Cariprazine (Major Depressive Disorder) Market Vendor Analysis, Forecast and Investment Trends to 2023

Cariprazine (Major Depressive Disorder) Market Current Trends, Size,

Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities

and Forecasts to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy

in patients with MDD who had an inadequate response to antidepressant therapy, and as of April

2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest

Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of

schizophrenia and bipolar disorder.

Browse full report on: http://www.radiantinsights.com/research/cariprazine-majordepressive-disorder-forecast-and-market-analysis-to-2023

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

- Detailed information on Cariprazine including product description, safety and efficacy profiles

as well as a SWOT analysis.

- Sales forecast for Cariprazine for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and

Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the...